Evan Lockwood Rachlin is Director at Iambic Therapeutics, Inc. (IAM). They have made 1 open-market trade across 1 company since 2026, most recently 2026-10-16.
CIK 2151678
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $11.5M since 2026, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| IAM | 2,588,248 | $34.6M |
Shares reported on the most recent Form 4, priced at the 2026-10-19 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| IAM | BUY | 2026-10-16 | 2026-10-19 | $16.00 | $11.5M | -10.0% | — | — |